Johannes Lemke1, Désirée Schäfer1, Silvia Sander2, Doris Henne-Bruns1, Marko Kornmann3. 1. Clinic of General and Visceral Surgery, University of Ulm, Ulm, Germany. 2. Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany. 3. Clinic of General and Visceral Surgery, University of Ulm, Ulm, Germany marko.kornmann@uniklinik-ulm.de.
Abstract
AIM: We analyzed survival of patients diagnosed with ampullary cancer (AC) and pancreatic ductal adenocarcinomas (PDAC). PATIENTS AND METHODS: Between 1996 and 2009, 505 and 69 patients diagnosed with PDAC and AC, respectively, were identified. Overall survival was analyzed according to tumor entity, therapeutic approach and pathological tumor stage. RESULTS: The 5-year overall survival rate of patients with AC (37%; 95% confidence interval 25-49%) was remarkably higher compared to PDAC patients (7%; 95% confidence interval 5-10%). In both cohorts, surgical resection improved survival. Analysis of pathological factors revealed a survival benefit for patients staged with small primary tumors (pT1/2) and exclusion of distant metastases (M0) for both PDAC and AC. Interestingly, absence of lymph node metastasis substantially improved survival in AC, but not in PDAC. CONCLUSION: Overall survival of patients with AC is superior compared to that of patients with PDAC. Therapeutically, adequate regional lymph node dissection seems particularly important for the surgical management of AC. Copyright
AIM: We analyzed survival of patients diagnosed with ampullary cancer (AC) and pancreatic ductal adenocarcinomas (PDAC). PATIENTS AND METHODS: Between 1996 and 2009, 505 and 69 patients diagnosed with PDAC and AC, respectively, were identified. Overall survival was analyzed according to tumor entity, therapeutic approach and pathological tumor stage. RESULTS: The 5-year overall survival rate of patients with AC (37%; 95% confidence interval 25-49%) was remarkably higher compared to PDACpatients (7%; 95% confidence interval 5-10%). In both cohorts, surgical resection improved survival. Analysis of pathological factors revealed a survival benefit for patients staged with small primary tumors (pT1/2) and exclusion of distant metastases (M0) for both PDAC and AC. Interestingly, absence of lymph node metastasis substantially improved survival in AC, but not in PDAC. CONCLUSION: Overall survival of patients with AC is superior compared to that of patients with PDAC. Therapeutically, adequate regional lymph node dissection seems particularly important for the surgical management of AC. Copyright
Authors: R Mantke; C Schneider; K Weylandt; S Gretschel; F Marusch; R Kube; A Loew; P Jaehn; C Holmberg; R Hunger Journal: Chirurgie (Heidelb) Date: 2022-01-07
Authors: Bobby V M Dasari; Keith J Roberts; James Hodson; Lewis Stevens; Andrew M Smith; Stefan G Hubscher; John Isaac; Paolo Muiesan; Robert P Sutcliffe; Ravi Marudanayagam; Darius F Mirza Journal: HPB (Oxford) Date: 2016-02-24 Impact factor: 3.647
Authors: Carolina Torres; Ana Linares; Maria José Alejandre; Rogelio J Palomino-Morales; Octavio Caba; Jose Prados; Antonia Aránega; Juan R Delgado; Antonio Irigoyen; Joaquina Martínez-Galán; Francisco M Ortuño; Ignacio Rojas; Sonia Perales Journal: Biomed Res Int Date: 2015-08-04 Impact factor: 3.411
Authors: Johannes Lemke; Jan Scheele; Thomas Kapapa; Silvia von Karstedt; Christian Rainer Wirtz; Doris Henne-Bruns; Marko Kornmann Journal: Int J Mol Sci Date: 2014-09-22 Impact factor: 5.923